A Biology Modality MCP review of FOLR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of EPOR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of ESR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of EGFR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of KDR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of CNR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of ADGRB2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of ADGRB1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A 2026 BD opportunity scan of Bedrock Therapeutics, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Balanced Pharma, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Atransen Pharma, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Ascendia Pharmaceutical Solutions, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.